UNSPSC 51433408: Quinapril hydrochloride

This classification denotes a tetrahydroisoquinoline, angiotensin-converting enzyme inhibitor, and antihypertensive agent with the molecular formula C25H30N2O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33067B3N2M, chemically known as 3-isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, monohydrochloride, (3s-(2(r*(r*)),3r*)) but more generally known as quinapril hydrochloride, which bears US NIH Compound Identifier 54891.

UNSPSC 51433408 Quinapril hydrochloride is a Commodity code tracking a specific antihypertensive pharmaceutical ingredient used in state and local emergency medical services, pharmacy benefit programs, and multistate cooperative purchasing agreements. State and local governments procure this and related generic pharmaceuticals primarily for emergency medical services operations, state health agency pharmacy benefit programs, and coordinated multistate purchasing initiatives that serve multiple state and local health systems. The issuing bodies span city fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across state agencies and local health facilities.

The code sees recent activity concentrated in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue, including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials with a response deadline of April 8, 2026, and an estimated contract value of $40,000, with a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount not to exceed $10,000. The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling future formal procurement intent. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (Solicitation S1070000015802) on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness scheduled for July 1, 2026, requiring vendor compliance with cGMP, DSCSA, and pricing through authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson.